ProfileGDS4814 / ILMN_1785061
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 68% 68% 66% 70% 65% 63% 65% 65% 71% 29% 66% 69% 66% 63% 64% 67% 63% 68% 67% 68% 63% 68% 65% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)67.149768
GSM780708Untreated after 4 days (C2_1)66.213968
GSM780709Untreated after 4 days (C3_1)61.90766
GSM780719Untreated after 4 days (C1_2)72.533470
GSM780720Untreated after 4 days (C2_2)60.870365
GSM780721Untreated after 4 days (C3_2)58.636363
GSM780710Trastuzumab treated after 4 days (T1_1)60.131165
GSM780711Trastuzumab treated after 4 days (T2_1)60.384665
GSM780712Trastuzumab treated after 4 days (T3_1)75.216971
GSM780722Trastuzumab treated after 4 days (T1_2)45.304129
GSM780723Trastuzumab treated after 4 days (T2_2)62.15966
GSM780724Trastuzumab treated after 4 days (T3_2)69.135169
GSM780713Pertuzumab treated after 4 days (P1_1)62.817766
GSM780714Pertuzumab treated after 4 days (P2_1)57.859863
GSM780715Pertuzumab treated after 4 days (P3_1)59.577364
GSM780725Pertuzumab treated after 4 days (P1_2)64.267367
GSM780726Pertuzumab treated after 4 days (P2_2)58.547363
GSM780727Pertuzumab treated after 4 days (P3_2)66.019168
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)63.782567
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)67.166768
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)58.155663
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)66.586768
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)60.15165